BCD-085

Originator investigational product
List of clinical studies

BCD-085 is one of the drug products in the clinical development program of BIOCAD.

BCD-085 (International Nonproprietary Name: netakimab) is an investigational drug for medical use, monoclonal antibody for the treatment of plaque psoriasis, active ankylosing spondylitis, and active psoriatic arthritis.

A monoclonal antibody is a protein created by scientists in the laboratory, similar to the immune system natural antibodies, designed to bind to a specific target in the human body. Netakimab specifically binds to interleukin-17A. Elevated levels of IL-17A lead to inflammatory reactions and the development of autoimmune diseases. The binding of interleukin-17A leads to a decrease in the activity of such diseases due to a pronounced anti-inflammatory effect.

Netakimab has been studied in a number of non-clinical studies in animals and clinical trials in adult patients, and is currently approved, in the form of a solution for subcutaneous administration, by the Ministry of Health of the Russian Federation for the treatment of moderate and severe plaque psoriasis, active ankylosing spondylitis in case of insufficient response to standard therapy, active psoriatic arthritis in case of insufficient response to standard therapy in adult patients.

The clinical trial BCD-085-16/PLANETA-KIDS is studying the effectiveness and safety of Netakimab in the treatment of moderate to severe plaque psoriasis in children over 6 years of age.

  1. State Register of Medicines.
  2. Efleira® (Netakimab) official website.

This website section contains information about an investigational drug for medical use.